Bausch Health Companies Inc. faces a major setback as its next-gen rifaximin (RED-C) Phase 3 trial failed, jeopardizing franchise extension. BHC’s financials remain precarious, with Q3 2025 operating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results